miR-30d-5p represses the proliferation, migration, and invasion of lung squamous cell carcinoma via targeting DBF4

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. doi:10.3322/caac.21492.
   Google Scholar
• Ghouri YA, Mian I, Blechacz B. Cancer review: cholangiocarcinoma. J Carcinog. 2015;14:1. doi:10.4103/1477-3163.151940.
   Google Scholar
• Chen Z, Fillmore CM, Hammerman PS, Kim CF, Wong KK. Non-small-cell lung cancers: a heterogeneous set of diseases. Nat Rev Cancer. 2014;14:535–546. doi:10.1038/nrc3775.
   Google Scholar
• Goodwin J, Neugent ML, Lee SY, et al. The distinct metabolic phenotype of lung squamous cell carcinoma defines selective vulnerability to glycolytic inhibition. Nat Commun. 2017;8:15503. doi:10.1038/ncomms15503.
   Google Scholar
• Kinoshita A, Onoda H, Fushiya N, et al. Staging systems for hepatocellular carcinoma: current status and future perspectives. World J Hepatol. 2015;7:406–424. doi:10.4254/wjh.v7.i3.406.
   Google Scholar
• Land SR, Liu Q, Wickerham DL, Costantino JP, Ganz PA. Cigarette smoking, physical activity, and alcohol consumption as predictors of cancer incidence among women at high risk of breast cancer in the NSABP P-1 trial. Cancer Epidemiol Biomarkers Prev. 2014;23(5):823–832. doi:10.1158/1055-9965.EPI-13-1105-T.
   Google Scholar
• Tejeda-Maldonado J, García-Juárez I, Aguirre-Valadez J, et al. Diagnosis and treatment of hepatocellular carcinoma: an update. World J Hepatol. 2015;7:362–376. doi:10.4254/wjh.v7.i3.362.
   Google Scholar
• Drilon A, Rekhtman N, Ladanyi M, Paik P. Squamous-cell carcinomas of the lung: emerging biology, controversies, and the promise of targeted therapy. Lancet Oncol. 2012;13:e418–e426. doi:10.1016/S1470-2045(12)70291-7.
   Google Scholar
• Gao M, Kong W, Huang Z, Xie Z. Identification of key genes related to lung squamous cell carcinoma using bioinformatics analysis. Int J Mol Sci. 2020;21(8):2994. doi:10.3390/ijms21082994.
   Google Scholar
• Bousset K, Diffley JF. The Cdc7 protein kinase is required for origin firing during S phase. Genes Dev. 1998;12:480–490. doi:10.1101/gad.12.4.480.
   Google Scholar
• Ogi H, Wang CZ, Nakai W, Kawasaki Y, Masumoto H. The role of the Saccharomyces cerevisiae Cdc7-Dbf4 complex in the replication checkpoint. Gene. 2008;414:32–40. doi:10.1016/j.gene.2008.02.010.
   Google Scholar
• Katoh M. Function and cancer genomics of FAT family genes (review). Int J Oncol. 2012;41:1913–1918. doi:10.3892/ijo.2012.1669.
   Google Scholar
• Marston AL. Meiosis: DDK is not just for replication. Curr Biol. 2009;19:R74–R76. doi:10.1016/j.cub.2008.12.003.
   Google Scholar
• Kwaepila N, Burns G, Leong AS. Immunohistological localisation of human FAT1 (hFAT) protein in 326 breast cancers. Does this adhesion molecule have a role in pathogenesis? Pathology. 2006;38:125–131. doi:10.1080/00313020600559975.
   Google Scholar
• Pessoa-Brandao L, Sclafani RA. CDC7/DBF4 functions in the translesion synthesis branch of the RAD6 epistasis group in Saccharomyces cerevisiae. Genetics. 2004;167:1597–1610. doi:10.1534/genetics.103.021675.
   Google Scholar
• Takayama Y, Mamnun YM, Trickey M, et al. Hsk1- and SCF(Pof3)-dependent proteolysis of S. pombe Ams2 ensures histone homeostasis and centromere function. Dev Cell. 2010;18:385–396. doi:10.1016/j.devcel.2009.12.024.
   Google Scholar
• Miller CT, Gabrielse C, Chen YC, Weinreich M. Cdc7p-Dbf4p regulates mitotic exit by inhibiting Polo kinase. PLoS Genet. 2009;5:e1000498. doi:10.1371/journal.pgen.1000498.
   Google Scholar
• Johnston LH, Thomas AP. A further two mutants defective in initiation of the S phase in the yeast Saccharomyces cerevisiae. Mol Gen Genet. 1982;186:445–448. doi:10.1007/BF00729467.
   Google Scholar
• Matthews LA, Guarne A. Dbf4: the whole is greater than the sum of its parts. Cell Cycle. 2013;12:1180–1188. doi:10.4161/cc.24416.
   Google Scholar
• Barkley LR, Santocanale C. MicroRNA-29a regulates the benzo[a]pyrene dihydrodiol epoxide-induced DNA damage response through Cdc7 kinase in lung cancer cells. Oncogenesis. 2013;2:e57. doi:10.1038/oncsis.2013.20.
   Google Scholar
• He Y, Lin J, Kong D, et al. Current state of circulating microRNAs as cancer biomarkers. Clin Chem. 2015;61:1138–1155. doi:10.1373/clinchem.2015.241190.
   Google Scholar
• Lu TX, Rothenberg ME. MicroRNA. J Allergy Clin Immunol. 2018;141:1202–1207. doi:10.1016/j.jaci.2017.08.034.
   Google Scholar
• Kumar B, Khaleghzadegan S, Mears B, et al. Identification of miR-30b-3p and miR-30d-5p as direct regulators of androgen receptor signaling in prostate cancer by complementary functional microRNA library screening. Oncotarget. 2016;7:72593–72607. doi:10.18632/oncotarget.12241.
   Google Scholar
• Hung CH, Chiu YC, Chen CH, Hu TH. MicroRNAs in hepatocellular carcinoma: carcinogenesis, progression, and therapeutic target. Biomed Res Int. 2014; 2014:1–11. (2014). doi:10.1155/2014/486407.
   Google Scholar
• Tarasov VA, Matishov DG, Shin EF, et al. Coordinated aberranit expression of miRNAs in colon cancer. Genetika. 2014;50:1232–1244.
   Google Scholar
• Larsen AC. Conjunctival malignant melanoma in Denmark. Epidemiology, treatment and prognosis with special emphasis on tumorigenesis and genetic profile. Acta Ophthalmol. 2016;94:842. doi:10.1111/aos.13207.
   Google Scholar
• Xu J, Wu C, Che X, et al. Circulating microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis. Mol Carcinog. 2011;50:136–142. doi:10.1002/mc.20712.
   Google Scholar
• Chen D, Guo W, Qiu Z, et al. MicroRNA-30d-5p inhibits tumour cell proliferation and motility by directly targeting CCNE2 in non-small cell lung cancer. Cancer Lett. 2015;362:208–217. doi:10.1016/j.canlet.2015.03.041.
   Google Scholar
• Song Y, Song C, Yang S. Tumor-suppressive function of miR-30d-5p in prostate cancer cell proliferation and migration by targeting NT5E. Cancer Biother Radiopharm. 2018;33:203–211. doi:10.1089/cbr.2018.2457.
   Google Scholar
• Sasi NK, Bhutkar A, Lanning NJ, MacKeigan JP, Weinreich M. DDK promotes tumor chemoresistance and survival via multiple pathways. Neoplasia. 2017;19:439–450. doi:10.1016/j.neo.2017.03.001.
   Google Scholar
• Pavel AB, Campbell JD, Liu G, et al. Alterations in bronchial airway miRNA expression for lung cancer detection. Cancer Prev Res. 2017;10(11):651–659. doi:10.1158/1940-6207.CAPR-17-0098.
   Google Scholar
• Gao L, He R-Q, Wu H-Y, et al. Expression signature and role of miR-30d-5p in non-small cell lung cancer: a comprehensive study based on in silico analysis of public databases and in vitro experiments. Cell Physiol Biochem. 2018;50(5):1964–1987. doi:10.1159/000494875.
   Google Scholar
• Han HS, Kim MJ, Han JH, et al. Bile-derived circulating extracellular miR-30d-5p and miR-92a-3p as potential biomarkers for cholangiocarcinoma. Hepatobiliary Pancreat Dis Int. 2020;19:41–50. doi:10.1016/j.hbpd.2019.10.009.
   Google Scholar
• Bjornetro T, Redalen KR, Meltzer S, et al. An experimental strategy unveiling exosomal microRNAs 486-5p, 181a-5p and 30d-5p from hypoxic tumour cells as circulating indicators of high-risk rectal cancer. J Extracell Vesicles. 2019;8:1567219. doi:10.1080/20013078.2019.1567219.
   Google Scholar
• Zhu Y, Liu J, Fan L, et al. Serum expression and significance of MicroRNA-30d-5p in esophageal squamous cell carcinoma. Int J Clin Exp Pathol. 2017;10:8677–8685.
   Google Scholar
• Jackson AL, Pahl PM, Harrison K, Rosamond J, Sclafani RA. Cell cycle regulation of the yeast Cdc7 protein kinase by association with the Dbf4 protein. Mol Cell Biol. 1993;13:2899–2908. doi:10.1128/mcb.13.5.2899.
   Google Scholar
• Sasi NK, Tiwari K, Soon FF, et al. The potent Cdc7-Dbf4 (DDK) kinase inhibitor XL413 has limited activity in many cancer cell lines and discovery of potential new DDK inhibitor scaffolds. PLoS One. 2014;9:e113300. doi:10.1371/journal.pone.0113300.
   Google Scholar